Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.

Trial Details

NCT ID

NCT06132503

Phase

PHASE1

Sponsor

Lantern Pharma Inc.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

LP-284

Locations (sample)

West Valley City, Utah, United States|40.69161,-112.00105

Key Eligibility Criteria

Male or female aged ≥ 18 years on the day of signing informed consent.
Patient is capable of giving signed informed consent as described in Section 11.3 which includes compliance with the requirements and restrictions …
Eastern Cooperative Oncology Group (ECOG) performance status: 0-2 at screening.
For Lymphoma patients. At least one bi-dimensionally measurable disease site. The lesion must have a greatest transverse diameter of at least 1.5 c…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →